Spots Global Cancer Trial Database for metastatic cervical carcinoma

Every month we try and update this database with for metastatic cervical carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dostarlimab and Cobolimab in Advanced Cervical Cancer	NCT06238635	Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi...	Dostarlimab Cobolimab	18 Years -	Beth Israel Deaconess Medical Center
Donafenib for Recurrent Cervical Cancer	NCT05310331	Targeted Therap... Chemotherapy Recurrent Cervi... Metastatic Cerv... Persistent Adva... Survival Outcom... Adverse Effect	Donafenib combi...	18 Years - 75 Years	Peking Union Medical College Hospital
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer	NCT04574635	Cervical Adenos... Cervical Squamo... Infiltrating Ce... Metastatic Cerv... Recurrent Cervi... Stage I Cervica... Stage IA Cervic... Stage IA1 Cervi... Stage IA2 Cervi... Stage IB Cervic... Stage IB1 Cervi... Stage IB2 Cervi... Stage IB3 Cervi... Stage II Cervic... Stage IIA Cervi... Stage IIA1 Cerv... Stage IIA2 Cerv... Stage IIB Cervi... Stage III Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IIIC Cerv... Stage IIIC1 Cer... Stage IIIC2 Cer... Stage IV Cervic... Stage IVA Cervi... Stage IVB Cervi...	Biospecimen Col...	18 Years -	Mayo Clinic
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer	NCT05310305	Immune Checkpoi... Anti-programmed... Radiotherapy Recurrent Cervi... Metastatic Cerv... Persistent Adva... Objective Remis... Progression-fre... Overall Surviva... Severe Adverse ...	Radiotherapy fo...	18 Years -	Peking Union Medical College Hospital
Dostarlimab and Cobolimab in Advanced Cervical Cancer	NCT06238635	Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi...	Dostarlimab Cobolimab	18 Years -	Beth Israel Deaconess Medical Center
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer	NCT04574635	Cervical Adenos... Cervical Squamo... Infiltrating Ce... Metastatic Cerv... Recurrent Cervi... Stage I Cervica... Stage IA Cervic... Stage IA1 Cervi... Stage IA2 Cervi... Stage IB Cervic... Stage IB1 Cervi... Stage IB2 Cervi... Stage IB3 Cervi... Stage II Cervic... Stage IIA Cervi... Stage IIA1 Cerv... Stage IIA2 Cerv... Stage IIB Cervi... Stage III Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IIIC Cerv... Stage IIIC1 Cer... Stage IIIC2 Cer... Stage IV Cervic... Stage IVA Cervi... Stage IVB Cervi...	Biospecimen Col...	18 Years -	Mayo Clinic
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer	NCT05310383	Recurrent Cervi... Metastatic Cerv... Persistent Cerv... Radiotherapy Immunotherapy Anti-programmed... Immune Checkpoi... Tislelizumab Objective Respo... Survival Outcom...	Tislelizumab pl...	18 Years -	Peking Union Medical College Hospital
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: